Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
R
214260
vs
K
KOSPI 200
Over the past 12 months, Raphas Co Ltd has underperformed KOSPI 200, delivering a return of -45% compared to KOSPI 200's +116% growth.
Stocks Performance
214260 vs KOSPI 200
Performance Gap
214260 vs KOSPI 200
Performance By Year
214260 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Raphas Co Ltd
Glance View
Raphas Co Ltd makes microneedle patches and related drug-delivery materials. These are tiny needle-based patches designed to deliver active ingredients through the skin more directly than a normal cream or sticker. The company also works on skincare and pharmaceutical patch products that use the same core technology. Its customers are mainly cosmetics companies, healthcare product brands, and other partners that want to use microneedle patches in finished consumer or medical products. Raphas usually sells through business-to-business contracts, supplying its technology, patch components, or finished products to partners that then market them under their own brands or in their own channels. What makes Raphas different is its role in the value chain: it sits between material science and end-market products. Instead of being a broad drug maker or a general beauty company, it focuses on the patch platform itself, which can be adapted for skincare, wellness, and some medical uses. That gives the company a specialized niche in skin-based delivery products.